Positron emission tomography imaging in melanoma and lymphoma

Whal, 1991, 18F-2-deoxy-2-Fluoro-D-glucose uptake into human tumor xenografts, Cancer, 7, 1544, 10.1002/1097-0142(19910315)67:6<1544::AID-CNCR2820670614>3.0.CO;2-0 Gritters, 1993, Initial assessment of positron emission tomography using 2-fluorine-18-fluoro-2-deoxy-d-glucose in the imaging of malignant melanoma, J Nucl Med, 34, 1420 Steinert, 1995, Malignant melanoma: Staging with whole-body positron emission tomography and 2-[F-18]-Fluoro-2-deocy-d-glucose, Radiology, 195, 705, 10.1148/radiology.195.3.7753998 Damien, 1996, Positron emission tomography in the detection and management of metastatic melanoma, Melanoma Research, 6, 325, 10.1097/00008390-199608000-00008 White, 2000, Management of node-positive melanoma in the era of sentinel node biopsy, Surg Oncol, 9, 119, 10.1016/S0960-7404(00)00042-6 Ackland, 2001, Comparison of positron emission tomography scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma, J Clin Oncol, 19, 2674, 10.1200/JCO.2001.19.10.2674 Wagner, 1999, Prospective study of fluorodeoxyglucose-positron emission tomography imaging of lymph node basins in melanoma patients undergoing sentinel node biopsy, J Clin Oncol, 17, 1508, 10.1200/JCO.1999.17.5.1508 Crippa, 2000, Which kinds of lymph node metastases can FDG PET detect? A clinical study in melanoma, J Nucl Med, 41, 1491 Wagner, 2001, FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume, J Surg Oncol, 77, 237, 10.1002/jso.1102 Tyler, 2000, Positron emission tomography scanning in malignant melanoma. Clinical utility in patients with stage III disease, Cancer, 89, 1019, 10.1002/1097-0142(20000901)89:5<1019::AID-CNCR11>3.3.CO;2-S Rinne, 1998, Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: Results of a prospective study of 100 patients, Cancer, 82, 1199, 10.1002/(SICI)1097-0142(19980501)82:9<1664::AID-CNCR11>3.0.CO;2-2 Valk, 1997, Cost effectiveness of whole body FDG PET imaging in metastatic melanoma, J Nucl Med, 363 Holder, 1998, Effectiveness of positron emission tomography for the detection of melanoma metastases, Ann Surg, 227, 764, 10.1097/00000658-199805000-00017 Eigtved, 2000, Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma, Eur J Nucl Med, 27, 70, 10.1007/PL00006666 Swetter, 2000, Positron emission tomography (PET) is superior to computerized tomography (CT) for metastatic staging in melanoma patients, Clin Positron Imaging, 3, 154, 10.1016/S1095-0397(00)00066-2 Paul, 1987, Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma, J Nucl Med, 28, 288 Newman, 1994, Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT, Radiology, 190, 111, 10.1148/radiology.190.1.8259386 Moog, 1997, Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging, Radiology, 203, 795, 10.1148/radiology.203.3.9169707 Moog, 1998, Extranodal malignant lymphoma: Detection with FDG PET versus CT, Radiology, 206, 475, 10.1148/radiology.206.2.9457202 Jerusalem, 1999, Whole-body FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma, Nucl Med Communications, 20, 13, 10.1097/00006231-199901000-00004 Moog, 1998, 18-F-fluorode-oxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow, J Clin Oncol, 16, 603, 10.1200/JCO.1998.16.2.603 Carr, 1998, Detection of lymphoma in bone marrow by whole-body positron emission tomography, Blood, 91, 3340, 10.1182/blood.V91.9.3340 Abella-Columna, 1996, Staging Hodgkin's disease by whole-body PET-FDG imaging, J Nucl Med, 37 Bangerter, 1998, Whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for accurate staging of Hodgkin's disease, Ann. Oncol., 9, 1117, 10.1023/A:1008486928190 Weidmann, 1999, Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease, Leuk Lymph, 34, 545, 10.3109/10428199909058482 Partridge, 2000, 2-Fluorine-18-fluoro-2-deoxy-D-glucose positron emission tomography in the pretreatement staging of Hodgkin's disease: Influence on patient management in a single institution, Ann Oncol, 11, 1273, 10.1023/A:1008368330519 Jerusalem, 2001, Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease, Haematologica, 86, 266 Hoh, 1997, Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma, J Nucl Med, 38, 343 de Wit, 1997, Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma, Ann Oncol, 8, S57, 10.1023/A:1008253917337 Jerusalem, 1999, Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging, Blood, 94, 429, 10.1182/blood.V94.2.429 Cremerius, 1998, Positron emission tomography with FDG to detect residual disease after therapy for malignant lymphoma, Nucl Med Communication, 19, 1055, 10.1097/00006231-199811000-00005 Zinzani, 1999, The role of positron emission tomography (PET) in the management of lymphoma patients, Ann Oncol, 10, 1181, 10.1023/A:1008327127033 Mikhaeel, 2000, 18-FDG-PET for the assessment of residual masses on CT following treatment of lymphomas, Ann Oncol, 11, S147, 10.1023/A:1008381115131 Spaepen, 2001, Prognostic value of positron emission tomography (PET) with fluorine-18 fluoro-deoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?, J Clin Oncol, 19, 414, 10.1200/JCO.2001.19.2.414 Hoekstra, 1993, Early treatment response in malignant lymphoma, as determined by planar fluorine-18-fluorodeoxyglucose scintigraphy, J Nucl Med, 34, 1706 Römer, 1998, Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose, Blood, 9, 4464 Jerusalem, 2000, Persistent tumor FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma, Haematologica, 85, 613 Buchmann, 2001, 2-(fluorine-18)fluoro-2-deoxy-D-glucose positron emission tomography in the detection and staging of malignant lymphoma. A bicenter trial, Cancer, 91, 889, 10.1002/1097-0142(20010301)91:5<889::AID-CNCR1078>3.0.CO;2-5 Dittmann, 2001, Comparison of 18FDG-PET with CT in the evaluation of patients with residual and recurrent Hodgkin's lymphoma, Oncol Rep, 8, 1393 Lang, 2001, Clinical relevance of positron emission tomography (PET) in the treatment control and relapse of Hodgkin's disease, Strahlenter Onkol, 3, 138, 10.1007/PL00002394